New research suggests that popular weight loss and diabetes medications, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), are associated with a significantly higher risk of hair loss. A study involving nearly 50,000 individuals found that users of GLP-1 receptor agonists were up to 68% more likely to experience alopecia compared to those on other diabetes drugs.
Experts utilized electronic patient data from the University of Pennsylvania Health System to compare hair loss rates among adults using GLP-1s for diabetes management with those on alternative medications such as SGLT-2 inhibitors and DPP-4 inhibitors. The findings, published in The British Medical Journal (BMJ), indicated that GLP-1 users had a 37% higher risk of alopecia than SGLT-2 inhibitor users and a 68% higher risk compared to DPP-4 inhibitor users.
Regulators in both the United States and the UK have received numerous reports linking these medications to hair loss. In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) reported hundreds of cases for tirzepatide and semaglutide in recent years. The U.S. Food and Drug Administration (FDA) has acknowledged evaluating this potential safety signal.
The study authors noted that the hair loss observed appears to be non-scarring alopecia, a form where hair follicles remain intact, suggesting the potential for hair regrowth. While hair loss may not cause physical harm, researchers highlighted its potential for significant psychosocial consequences, impacting self-esteem, quality of life, and treatment adherence.
While the exact mechanism remains under investigation, researchers propose that rapid weight loss and reduced caloric intake associated with these drugs could trigger physiological stress and micronutrient deficiencies, disrupting the hair growth cycle. Other potential factors include the drugs' metabolic, hormonal, and immunological effects on hair follicles. Changes in thyroid function and altered absorption of other medications due to delayed gastric emptying have also been suggested as contributing elements.
GLP-1 receptor agonists mimic hormones that regulate appetite and have demonstrated effectiveness in managing chronic diseases and promoting substantial weight loss. Despite the potential side effect of hair loss, experts emphasize the drugs' well-established benefits for glycemic control, weight reduction, and lowering the risk of obesity-related complications. The absolute risk of hair loss is considered relatively low, and for many patients, the benefits of these medications are thought to outweigh this potential risk.